-
Illumina Announces Basespace Genomic App Store
Apr 26, 2012, 01:00 AM by Michael CroftXconomy | Illumina announced an open platform for genomic apps at the Bio-IT World Conference & Expo yesterday. Basespace Apps will use the Amazon cloud and let users download various genomic software options.Full story -
Hello Siri, Please Start My Experiment Now
Apr 25, 2012, 15:05 PM by Michael CroftBio-IT World | BOSTON -- BT Global Services showed the first use of Siri, the Apple iPhone’s voice-activated natural language processing technology, to launch, run and deliver the results of an experiment in the newly announced BT Cloud today at the Bio-IT World Expo.Full story -
Bio-It World Announces Winners of 2012 Best Practices Awards
Apr 25, 2012, 07:30 AM by Michael CroftBio-IT World | BOSTON—Bio-IT World announced the winners of its eighth Best Practices Awards competition this morning in a plenary session at the 2012 Bio-IT World Conference & Expo in Boston. Grand Prize winners from five life sciences awards categories included entries from three big pharma companies—Merck, Pfizer, and Merck KGaA (Germany)—and two genomics organizations, BGI Shenzhen and the University of Utah/Omicia.Full story -
Lombardi Lays Out His Vision for Real Time Genomics
Apr 25, 2012, 06:10 AM by Michael CroftBio-IT World | BOSTON—Less than two weeks into his new position as CEO of Real Time Genomics (RTG), Steve Lombardi shared some of his early vision with Bio-IT World, judging this week’s conference to be the perfect venue to make the official announcement.Full story -
10,000 Names In, What the Boycott Means for Elsevier, Open Access
Apr 25, 2012, 05:00 AM by Michael CroftThe Guardian | With more than 10,000 scientists pledging to boycott Elsevier on the Cost of Knowledge website, the site's creator, Tyler Neylon, talks about open access and what will come next for scientific publishing.Full story -
Twitter Highlights from Bio-IT World Keynotes
Apr 25, 2012, 00:00 AM by Michael CroftBio-IT World | The 10th Anniversary of the Bio-IT World Conference and Expo kicked off yesterday evening. With over 2,500 registered attendees, the anniversary event is already proving to be a record breaker. Opening keynote presentations by Jill P. Mesirov, Associate Director and Chief Informatics Officer; Director, Computational Biology and Bioinformatics and Martin Leach, CIO, both of the Broad Institute of MIT and Harvard were chronicled by hundreds of tweets.Full story -
Amazon Announces Asia Pac Beanstalk Expansion, Rumors of Data Centers in Sydney, Hong Kong
Apr 24, 2012, 00:45 AM by Michael CroftRoundup | Amazon is expanding the availabilty of the AWS Elastic Beanstalk to Japan, making the service available to developers in the US East and now Asia Pacific regions, and Amazon's newest data centers are rumored to be in the works for Sydney and Hong Kong.Full story -
454, MiSeq, and PGM Go Head to Head
Apr 23, 2012, 04:30 AM by Michael CroftNature | A group of UK-based researchers compare the newest breed of sequencers: Roche’s 454 GS Junior, Illumina’s MiSeq and Life Technologies’ Ion Torrent Personal Genome Machine (PGM).Full story -
The Foundation Approach to Drug Discovery
Apr 23, 2012, 04:00 AM by Michael CroftThe Atlantic | There's been much debate about the best drug discovery business model, with the weaknesses of both academia and pharma made painfully clear. But perhaps the best business model is being practiced by translation-focused disease foundations.Full story -
Human Genome Sciences Rejects GSK Offer
Apr 20, 2012, 00:10 AM by Michael CroftBloomberg BusinessWeek | In a second buyout rejection this week, Human Genome Sciences rejected a $2.59 billion acquisition bid from GlaxoSmithKline. The two companies currently partner on a lupus treatment.Full story -
Going Up: Cycle Launches 50,000-Core Utility Supercomputer in the Cloud
Apr 19, 2012, 08:15 AM by Michael CroftBio-IT World | In the latest in a string of cloud computing firsts, Cycle Computing has collaborated with Schrödinger and Nimbus Discovery to spin up a 50,000-core supercomputer in the Amazon Web Services (AWS) cloud.Full story -
GSK Signs $30m Deal for Asthma, COPD Drugs
Apr 19, 2012, 03:00 AM by Michael CroftSan Francisco Business Times | GlaxoSmithKline has signed a second collaboration with Five Prime Therapeutics to develop drugs for asthma and COPD. Five Prime is eligible to receive payments up to $30 million over the next four years.Full story -
Illumina Holds On to Board of Directors, Company
Apr 19, 2012, 02:30 AM by Michael CroftDealBook | Roche walked away from the table yesterday after Illumina shareholders voted to re-elect all of Illumina's directors by a large margin. On Wednesday, Illumina shares closed at $44.51, one cent higher than Roche's inital bid.Full story -
Decision Day for Illumina, Roche
Apr 18, 2012, 02:10 AM by Michael CroftRoundup | Today is Illumina's board meeting, and there is much theorizing about the outcome. After two rejected bids, Roche has nominated six directors and proposed expanding the Illumina board to 11 members. Illumina--along with two independent advisory firms--has recommended that shareholders vote for the four Illumina nominees.Full story -
Wingu Announces Google Funding
Apr 18, 2012, 00:05 AM by Michael CroftDigital Journal | Wingu, a developer of software designed to enhance the operational efficiency of pharmaceutical research and discovery, announced a Series A round of funding led by Google Ventures with additional investment from Borealis Ventures.Full story -
DecisionView’s Consortium Approach to Optimizing Enrollment
Apr 17, 2012, 04:10 AM by Michael CrofteCliniqua | For industry leader Merck, country-specific and site-level performance metrics have been among the early wins from the DecisionView Enrollment Benchmarks data set, says Brendan O’Neill, Merck’s director and head of global trial optimization. The pharmaceutical giant last June joined peers GlaxoSmithKline and Roche in working with DecisionView to turn their combined operational patient enrollment data into a cross-industry set of clinical trial enrollment benchmarks.Full story -
Merck Acquires Cancer Drug Rights
Apr 17, 2012, 04:00 AM by Michael CroftReuters | Merck has acquired the rights to an Endocyte cancer drug candidate for $120 million and up to $880 million in milestone payments.Full story -
Geneticists Respond to DNA Prediction Study
Apr 17, 2012, 03:40 AM by Michael CroftFull storyUCSF | Genetics experts respond to recent press about the limits of personal genomics. In a nutshell: well duh!
-
Structure-Based Drug Design for Pharma
Apr 17, 2012, 03:20 AM by Michael CroftWall Street Journal | Computer-aided drug design (or structure-based design) is taking off in pharma with Pfizer, Lilly, GlaxoSmithKline, and Sanofi all using structure-based design in recently launched or late-stage compounds.Full story -
Customer Centricity in Life Sciences
Apr 16, 2012, 03:05 AM by Michael CroftFull storyBio-IT World | Guest Commentary | A fundamental requirement for success in the life sciences industry is the ability to communicate effectively and in a timely manner with all customers (i.e. health care professionals and patients). In an ideal world, life sciences companies would have all the information about any given customer at their fingertips. However, even if this were possible, the information is of little value if you cannot utilize it to better serve your customers at the point of interaction, across all contact channels and organizational silos.